ACASTI PHARMA INC (ACST) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ACST • CA00430K8656

3.37 USD
-0.03 (-0.88%)
At close: Oct 25, 2024
3.38 USD
+0.01 (+0.3%)
After Hours: 10/25/2024, 8:22:28 PM
Fundamental Rating

3

ACST gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. ACST has a great financial health rating, but its profitability evaluates not so good. ACST does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ACST had negative earnings in the past year.
  • In the past year ACST has reported a negative cash flow from operations.
  • In the past 5 years ACST always reported negative net income.
  • ACST had a negative operating cash flow in each of the past 5 years.
ACST Yearly Net Income VS EBIT VS OCF VS FCFACST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • ACST has a better Return On Assets (-16.41%) than 65.98% of its industry peers.
  • ACST has a better Return On Equity (-19.28%) than 73.20% of its industry peers.
Industry RankSector Rank
ROA -16.41%
ROE -19.28%
ROIC N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
ACST Yearly ROA, ROE, ROICACST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • ACST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACST Yearly Profit, Operating, Gross MarginsACST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ACST has been increased compared to 1 year ago.
  • The number of shares outstanding for ACST has been increased compared to 5 years ago.
  • There is no outstanding debt for ACST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACST Yearly Shares OutstandingACST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ACST Yearly Total Debt VS Total AssetsACST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • ACST has an Altman-Z score of -2.64. This is a bad value and indicates that ACST is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -2.64, ACST perfoms like the industry average, outperforming 40.21% of the companies in the same industry.
  • ACST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.64
ROIC/WACCN/A
WACCN/A
ACST Yearly LT Debt VS Equity VS FCFACST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 7.86 indicates that ACST has no problem at all paying its short term obligations.
  • ACST has a Current ratio of 7.86. This is in the better half of the industry: ACST outperforms 78.35% of its industry peers.
  • ACST has a Quick Ratio of 7.86. This indicates that ACST is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.86, ACST is in the better half of the industry, outperforming 78.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.86
Quick Ratio 7.86
ACST Yearly Current Assets VS Current LiabilitesACST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 78.32% over the past year.
EPS 1Y (TTM)78.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.76% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.02%
EPS Next 2Y4.97%
EPS Next 3Y24.24%
EPS Next 5Y22.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACST Yearly Revenue VS EstimatesACST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
ACST Yearly EPS VS EstimatesACST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ACST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACST Price Earnings VS Forward Price EarningsACST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACST Per share dataACST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • ACST's earnings are expected to grow with 24.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.97%
EPS Next 3Y24.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ACST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ACASTI PHARMA INC

NASDAQ:ACST (10/25/2024, 8:22:28 PM)

After market: 3.38 +0.01 (+0.3%)

3.37

-0.03 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-09
Earnings (Next)11-11
Inst Owners20.9%
Inst Owner Change0.31%
Ins Owners53.95%
Ins Owner Change0%
Market Cap34.17M
Revenue(TTM)N/A
Net Income(TTM)-11.44M
Analysts82.86
Price Target8.16 (142.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.19%
Min EPS beat(2)-6.26%
Max EPS beat(2)62.63%
EPS beat(4)2
Avg EPS beat(4)-1.86%
Min EPS beat(4)-69.34%
Max EPS beat(4)62.63%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)33.33%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-42.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 3.38
EV/EBITDA N/A
EPS(TTM)-1.04
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS5.85
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.41%
ROE -19.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.86
Quick Ratio 7.86
Altman-Z -2.64
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.66%
EPS Next Y-11.02%
EPS Next 2Y4.97%
EPS Next 3Y24.24%
EPS Next 5Y22.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.69%
OCF growth 3YN/A
OCF growth 5YN/A

ACASTI PHARMA INC / ACST FAQ

What is the fundamental rating for ACST stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACST.


Can you provide the valuation status for ACASTI PHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to ACASTI PHARMA INC (ACST). This can be considered as Overvalued.


Can you provide the profitability details for ACASTI PHARMA INC?

ACASTI PHARMA INC (ACST) has a profitability rating of 1 / 10.


Can you provide the financial health for ACST stock?

The financial health rating of ACASTI PHARMA INC (ACST) is 7 / 10.


What is the expected EPS growth for ACASTI PHARMA INC (ACST) stock?

The Earnings per Share (EPS) of ACASTI PHARMA INC (ACST) is expected to decline by -11.02% in the next year.